Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuraxis (NRXS) Capital Expenditures (2022 - 2025)

Neuraxis' Capital Expenditures history spans 4 years, with the latest figure at $7288.0 for Q2 2025.

  • For Q2 2025, Capital Expenditures fell 16.09% year-over-year to $7288.0; the TTM value through Sep 2025 reached $25288.0, down 42.29%, while the annual FY2024 figure was $27776.0, 9.76% down from the prior year.
  • Capital Expenditures for Q2 2025 was $7288.0 at Neuraxis, down from $18000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $18000.0 in Q1 2025 and bottomed at -$10000.0 in Q4 2022.
  • The 4-year median for Capital Expenditures is $7448.0 (2023), against an average of $7384.5.
  • The largest annual shift saw Capital Expenditures soared 260.4% in 2023 before it fell 16.09% in 2025.
  • A 4-year view of Capital Expenditures shows it stood at -$10000.0 in 2022, then skyrocketed by 260.4% to $16040.0 in 2023, then plummeted by 72.77% to $4368.0 in 2024, then surged by 66.85% to $7288.0 in 2025.
  • Per Business Quant, the three most recent readings for NRXS's Capital Expenditures are $7288.0 (Q2 2025), $18000.0 (Q1 2025), and $4368.0 (Q3 2024).